Oncology

Latest News

Analyzed by birth cohort, the authors found each successive birth cohort had a 7.7% decline in SCLC rates. | Image credit: shidlovski

Decline in SCLC Incidence Expected to Accelerate Through 2050

By Jared Kaltwasser

June 29th 2025

The incidence of small cell lung cancer (SCLC) is projected to drop by 5.9% each year through 2050.

While elevated NLR previously served as a marker of aggressive disease and poor prognosis in SCLC, its prognostic relevance appears to diminish in the context of immunotherapy-based treatment regimens. | Image credit: Crystal light - stock.adobe.com

Challenging the Prognostic Role of NLR in SCLC in the Era of Immunotherapy

By Kimberly Rath, PharmD

June 27th 2025

Gender rights | Image Credit: © Nadzeya-stock.adobe.com

Culture Key to Data Collection of Sexual Orientation and Gender Identity in Cancer Care

By Maggie L. Shaw

June 23rd 2025

AJMC Q&A with Coral Omene, MD, PhD | Background image credit: ipopba - stock.adobe.com

Addressing Cancer Care Challenges for Patients, and Ensuring Equity: Coral Omene, MD, PhD

By Laura Joszt, MA
Coral Omene, MD, PhD

June 22nd 2025

Patients with SCLC in the tarlatamab group had significantly longer overall survival, with a median of 13.6 months vs 8.3 months in the chemotherapy group. | Image credit: mi_viri - stock.adobe.com

Tarlatamab Improves SCLC Outcomes After Platinum Chemotherapy

By Jared Kaltwasser

June 19th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

View All

July 6th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

July 6th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

January 8th 2017

Stuart Genschaw Discusses His Practice's Transition Towards Implementing the OCM

As Cancer & Hematology Centers of Western Michigan starts to participate in the Oncology Care Model (OCM), it has dedicated its resources to understanding the model and analyzing data, said Stuart Genschaw, executive director of the Cancer & Hematology Centers of Western Michigan. Throughout this process, however, the practice’s main focus is always on “providing great care” to its patients.

January 6th 2017

CDC Invites Comments on Phase 3 of "The Campaign"

Surabhi Dangi-Garimella, PhD

CDC has opened up a portal for public comments on its National Tobacco Prevention and Control Public Education Campaign to gather input on the effectiveness of its existing efforts on data collection.

January 6th 2017

This Week in Managed Care: January 6, 2017

This week in managed care, readers chose the top healthcare news story of 2016, 4 physician groups appealed to Congress to have a replacement for Obamacare ready if it is repealed, and the American College of Physicians released a new guideline on oral medications for type 2 diabetes.

January 5th 2017

HTA Study Raises Questions on Real-World Benefits of Newly Approved Cancer Drugs

Surabhi Dangi-Garimella, PhD

While rapid innovations in the field of oncology have improved treatments, the magnitude and dimension of clinical benefits vary widely.

January 5th 2017

What We're Reading: Biden's Post-White House Plans Include Nonprofit Cancer Initiative

AJMC Staff

What we’re reading, January 5, 2017: Vice President Joe Biden will create a nonprofit organization to focus on cancer research and drug prices; school telemedicine could help kids stay in the classroom and out of the doctor’s office; bundled payments for joint replacements saved $5577 in spending per episode.

January 5th 2017

Dr David L. Porter: Combining CAR-T Cells With Other Immunotherapies the Next Logical Step

David L. Porter, MD, of the University of Pennsylvania Health System, explains why treating tumors with a combination of CAR-T cells and other immune-stimulating agents is a logical next step for investigators.

January 4th 2017

Optimizing Weight-Loss Interventions in Women Cancer Survivors

AJMC Staff

Researchers in Australia conducted a systematic analysis of several randomized control trials that evaluated weight loss as an intervention for breast, endometrial, and ovarian cancer.

January 4th 2017

CAR-T Treatment in Glioblastoma: Will the Effect Be Sustained?

Surabhi Dangi-Garimella, PhD

A new single-patient case study, published in the New England Journal of Medicine, has raised the possibility of using CAR-T cells in the treatment of glioblastoma, an aggressive form of brain tumor.

January 4th 2017

Debra Madden on Unrealistic Expectations For Immuno-Oncology Treatments

Many patients have learned about the advances in immunotherapy treatments for cancer, but the media may not be portraying all the complexities and potential harms of these agents, according to Debra L. Madden, cancer research advocate and patient representative. Madden mentioned that biomarker research could help determine which patients are most likely to benefit from immuno-oncology.

January 3rd 2017

First Patient Treated With Jakafi in Phase 2 Graft-Versus-Host Disease Study

AJMC Staff

The first patient has been treated with ruxolitinib (Jakafi), by Incyte Corporation, for steroid-refractory acute graft-versus-host disease, as part of the REACH-1 phase 2 trial. The trial is evaluating ruxolitinib in combination with corticosteroids.

January 2nd 2017

Dr Carrie Stricker Discusses the Importance of the Patient Voice in Oncology Treatment Decisions

Oncologists must recognize the importance of the patient voice when making treatment decisions so that the treatment plan can be adapted to each patient’s goals and desires, said Carrie Stricker, PhD, RN, AOCN, chief clinical officer and co-founder of Carevive.

January 1st 2017

Pam Mangat Discusses ASCO's Progress on TAPUR Study

The TAPUR clinical trial is rapidly expanding to new sites, but the researchers have not yet collected enough data to analyze and publish the results, according to Pam Mangat, MS, associate director TAPUR study at the American Society of Clinical Oncology.

December 31st 2016

Examining the Uterine Lavage Fluid for Early Signs of Endometrial Cancer

Surabhi Dangi-Garimella, PhD

According to a new study published in PLOS Medicine, genetic analysis of the uterine lavage fluid from pre- and post-menopausal women can provide early evidence of endometrial cancer.

December 30th 2016

Conference Stories That Captivated AJMC® Readers in 2016

Surabhi Dangi-Garimella, PhD

A glimpse at the top 5 articles from The American Journal of Managed Care'sÂ® conference coverage that caught reader attention in 2016.

December 29th 2016

Midwestern States Witness Significant Increase in Melanoma Deaths Over a Decade

Surabhi Dangi-Garimella, PhD

Twenty-three of 48 states in the United States saw a drop in melanoma—associated death in 2013 compared with 2003, while 21 states witnessed a rise in the death rate.

December 29th 2016

Samantha Watson Discusses Cancer's Financial Impact on Young Adults

Cancer care and its associated costs can combine with everyday bills to create a significant financial burden, especially for young adults with cancer, said Samantha Watson, founder and CEO of The Samfund.

December 28th 2016

Reducing Radiation Dose in Oropharynx Cancer Can Improve QOL

Surabhi Dangi-Garimella, PhD

A new clinical study to reduce the unwanted side effects of radiation in patients with human papillomavirus (HPV)—positive oropharynx cancers has found that reducing the dose of radiation can maintain the cure rates but avoid some of the late treatment-associated toxicities.

December 27th 2016

Surabhi Dangi-Garimella, PhD

As 2016 draws to a close, here’s a look at the top 5 news articles that captured reader interest on AJMC.com.

December 26th 2016

Jonathan Hirsch on Making Data Usable for Oncologists at the Point of Care

Oncology care is often spread out across multiple facilities and providers, so health IT innovators use software to integrate data from these many locations and deliver it to the point of care, according to Jonathan Hirsch, founder and president of Syapse.

December 24th 2016

Dr Sean Khozin Discusses How FDA Regulatory Process Helps Advance Precision Oncology

FDA’s regulatory science activities are working to advance the field of precision oncology, in part by using predictive analyses to identify patients that may be good candidates for certain therapies, according to Sean Khozin, MD, MPH, senior medical officer at the FDA.

December 23rd 2016

SWOG Trial Results Could Lead to New Standard of Care in Multiple Myeloma

Surabhi Dangi-Garimella, PhD

The Lancet study shows addition of bortezomib significantly improves survival in treatment-naÃ¯ve patients with multiple myeloma.

December 23rd 2016

Precision Treatment Would Benefit Patients With Glioblastoma, Stanford Analysis Finds

Surabhi Dangi-Garimella, PhD

Using angiogenesis inhibitors in patients with glioblastoma that is highly vascularized could yield much improved outcomes, the analysis found.

December 23rd 2016

This Week in Managed Care: December 23, 2016

This week, the top managed care stories included CMS announcing more mandatory bundled payment models and a new track in the Medicare Shared Savings Program, the FDA approving a new use for Dexcom's continuous glucose monitor, and a greater emphasis on lifestyle management in the American Diabetes Association's care standards.

December 23rd 2016

Dr Stuart Goldberg on How to Collect Data in a Way That Makes Oncologic Sense

The kind of data oncologists need to move towards value-based care isn’t easily accessible in patient electronic health records, but new platforms like Cancer Outcomes Tracking and Analysis (COTA) are trying to make it easier, said Stuart Goldberg, MD, chief medical officer, COTA, John Theurer Cancer Center.

December 22nd 2016

Patient-Physician Communication Can Influence Decisions on CPM, Avoid Overtreatment

Surabhi Dangi-Garimella, PhD

A new study has found that women chose not to go ahead with contralateral prophylactic mastectomy (CPM) if their surgeon recommended against it.

December 22nd 2016

FDA Urges Researchers to Enroll Adolescents in Adult Oncology Trials

Surabhi Dangi-Garimella, PhD

Adolescents who have “adult-type” cancers should be enrolled in relevant clinical trials to improve access for this population of patients, experts from the FDA write in a recently published perspective.

December 21st 2016

Using a Tumor's Genomic Signature to Guide Radiation Therapy Doses

Surabhi Dangi-Garimella, PhD

Researchers at the Moffitt Cancer Center have developed a genomics model called genomic-adjusted radiation dose that can guide the radiation dose to match a tumor’s radiosensitivity.

December 20th 2016

Expert Insights: Most Popular Videos, Interviews, and Podcasts in 2016

Laura Joszt, MA

Along with the peer-review research, journal articles, and news coverage, The American Journal of Managed Careâ„¢ (AJMCâ„¢) has a robust multimedia component that brings together stakeholders from across the healthcare industry to discuss important topics in the world of managed care and delve deeper into topics.

December 20th 2016

Will the FDA Replicate the Oncology Center of Excellence?

Surabhi Dangi-Garimella, PhD

The 21st Century Cures Act mandates the creation of "one or more" intercenter institutes at the FDA. But is such a massive reorganization feasible within the FDA?

December 19th 2016

First NGS-Based Companion Diagnostic Approved With Rucaparib for Advanced Ovarian Cancer

AJMC Staff

The FDA has provided accelerated approval for rupacarib along with the first next-generation sequencing—based companion diagnostic test, for the treatment of women with advanced ovarian cancer.

...

85 86 87 88 89 90 91 92 93

...

186 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions